# antibodies -online.com







# anti-CARM1 antibody (pSer228)

**Images** 



| $\sim$  |       |
|---------|-------|
| ( )\/\  | rview |
| $\circ$ |       |

| Quantity:            | 100 μL  |
|----------------------|---|
| Target:              | CARM1   |
| Binding Specificity: | pSer228   |
| Reactivity:          | Human   |
| Host:                | Rabbit  |
| Clonality:           | Polyclonal  |
| Conjugate:           | This CARM1 antibody is un-conjugated                  |
| Application:         | Western Blotting (WB), ELISA, Immunofluorescence (IF) |

### **Product Details**

| Immunogen:        | Peptide sequence around phosphorylation site of serine 228(V-K-S(p)-N-N) derived from Human CARM1.  |
|-------------------|---|
| Isotype:          | IgG   |
| Cross-Reactivity: | Human, Mouse, Rat   |
| Purification:     | Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific |
|                   | phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi   |

## **Target Details**

| Target:           | CARM1                  |
|-------------------|------------------------|
| Alternative Name: | CARM1 (CARM1 Products) |

Background:

Background:

Methylates (mono- and asymmetric dimethylation) the quanidino nitrogens of arginyl residues in several proteins involved in DNA packaging, transcription regulation, pre-mRNA splicing, and mRNA stability. Recruited to promoters upon gene activation together with histone acetyltransferases from EP300/P300 and p160 families, methylates histone H3 at 'Arg-17' (H3R17me), forming mainly asymmetric dimethylarginine (H3R17me2a), leading to activate transcription via chromatin remodeling. During nuclear hormone receptor activation and TCF7L2/TCF4 activation, acts synergically with EP300/P300 and either one of the p160 histone acetyltransferases NCOA1/SRC1, NCOA2/GRIP1 and NCOA3/ACTR or CTNNB1/beta-catenin to activate transcription. During myogenic transcriptional activation, acts together with NCOA3/ACTR as a coactivator for MEF2C. During monocyte inflammatory stimulation, acts together with EP300/P300 as a coactivator for NF-kappa-B. Acts as coactivator for PPARG, promotes adipocyte differentiation and the accumulation of brown fat tissue. Plays a role in the regulation of pre-mRNA alternative splicing by methylation of splicing factors. Also seems to be involved in p53/TP53 transcriptional activation. Methylates EP300/P300, both at 'Arq-2142', which may loosen its interaction with NCOA2/GRIP1, and at 'Arg-580' and 'Arg-604' in the KIX domain, which impairs its interaction with CREB and inhibits CREB-dependent transcriptional activation. Also methylates arginine residues in RNA-binding proteins PABPC1, ELAVL1 and ELAV4, which may affect their mRNA-stabilizing properties and the half-life of their target mRNAs

Aliases: PRMT4

UniProt:

A6NN38

Pathways:

Intracellular Steroid Hormone Receptor Signaling Pathway, Regulation of Intracellular Steroid
Hormone Receptor Signaling, Regulation of Lipid Metabolism by PPARalpha, Regulation of
Muscle Cell Differentiation, Skeletal Muscle Fiber Development, Positive Regulation of fat Cell
Differentiation

#### **Application Details**

Application Notes: WB:1:500-1:1000, IF:1:100-1:200,

Restrictions: For Research Use only


Handling

Format: Liquid

#### Handling


| Buffer:            | Supplied at 1.0 mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol. |
|--------------------|---|
| Preservative:      | Sodium azide  |
| Precaution of Use: | This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.                  |
| Storage:           | -20 °C,-80 °C   |
| Storage Comment:   | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.   |

#### **Images**



#### **Immunofluorescence**

**Image 1.** Immunofluorescence staining of methanol-fixed HeLa cells using CARM1 (Phospho-Ser228) antibody.



#### **Western Blotting**

**Image 2.** Western blot analysis of extracts from A431 cells untreated or treated with EGF (200 ng/mL, 5 min), using CARM1 (Ab-228) antibody (Line 1 and 2) and CARM1 (Phospho-Ser228) antibody (Line 3 and 4).